Patents Assigned to Eleison Pharmaceuticals LLC
  • CRYSTALLINE POLYMORPHS OF 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL
    Publication number: 20220213014
    Abstract: Described herein are polymorphic forms of 1,6-dibromo-1,6-dideoxy-dulcitol (dibromo dulcitol or DBD), which is a known antitumor agent.
    Type: Application
    Filed: March 24, 2022
    Publication date: July 7, 2022
    Applicant: Eleison Pharmaceuticals LLC
    Inventors: Stefano Luca Giaffreda, Elena Dichiarante
  • COMBINATION THERAPEUTIC REGIMENS WITH 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL
    Publication number: 20220142941
    Abstract: Methods of treating a subject suffering from a brain tumor are described herein wherein said methods comprise administering a therapeutically effective amount of a crystalline polymorph of 1,6-dibromo-1,6-dideoxy-dulcitol (DBD) including combination therapies with synergistic second cancer treatments. Also disclosed are methods of screening subjects sensitive to a crystalline DBD polymorph and treating those subjects demonstrating sensitivity.
    Type: Application
    Filed: April 22, 2020
    Publication date: May 12, 2022
    Applicant: Eleison Pharmaceuticals LLC
    Inventors: Patrick Maguire, Robert Johnston, Seth Lederman
  • Crystalline polymorphs of 1,6-dibromo-1,6-dideoxy-dulcitol
    Patent number: 11312675
    Abstract: Described herein are polymorphic forms of 1,6-dibromo-1,6-dideoxy-dulcitol (dibromo dulcitol or DBD), which is a known antitumor agent. Also described are methods of making these new crystalline polymorphic forms as well as methods of using these polymorphic forms to treat cancer.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: April 26, 2022
    Assignee: Eleison Pharmaceuticals, LLC
    Inventors: Stefano Luca Giaffreda, Elena Dichiarante
  • Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
    Patent number: 11291644
    Abstract: The described invention provides methods for treating pulmonary cancer in a subject, by administering to the subject by inhalation a composition of inhalational lipid cisplatin (ILC) comprising a lipid-complexed cisplatin.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: April 5, 2022
    Assignee: ELEISON PHARMACEUTICALS, LLC
    Inventors: Forrest H. Anthony, Matthew M. Parris, Edwin J. Thomas, Guangtao Zhang
  • Glufosfamide Combination Therapies for Cancer
    Publication number: 20130281386
    Abstract: The invention provides compositions and methods for treating cancer with glufosfamide in combination with an inhibitor of sodium-glucose transporter type 2 (SGLT2) to block the uptake of glucose in the proximal tubules of the kidneys to decrease renal toxicity. The invention relates to the fields of biomedicine, pharmacology, and molecular biology.
    Type: Application
    Filed: August 30, 2012
    Publication date: October 24, 2013
    Applicant: Eleison Pharmaceuticals LLC
    Inventors: Forrest H. Anthony, Edwin J. Thomas, Matthew Parris